Application
JNK-IN-8 has been used as an inhibitor to address the importance of JNK signaling in withaferin A (WFA)-induced apoptosis of myelodysplastic syndromes (MDS)-L cells.
Biochem/physiol Actions
JNK-IN-8 is a potent, selective and irreversible inhibitor of JNK1/2/3 that inhibits phosphorylation of c-Jun. JNK-IN-8 forms covalent bonds with a conserved cysteine residue.
JNK-IN-8 and lapatinib synergistically reduce cell viability in human triple negative breast cancers (TNBC) cell lines by inducing apoptosis. JNK-IN-8 and lapatinib result in accumulation of cytotoxic oxidative stress.
Other Notes
JNK-IN-8 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the JNK-IN-8 probe summary on the Chemical Probes Portal website.
Packaging
5, 25 mg in glass bottle
| Colour | white to beige |
|---|---|
| Quality Level | 100 |
| InChI key | GJFCSAPFHAXMSF-UHFFFAOYSA-N |
| InChI | 1S/C29H29N7O2/c1-20-17-24(11-12-25(20)34-29-31-15-13-26(35-29)22-8-5-14-30-19-22)33-28(38)21-7-4-9-23(18-21)32-27(37)10-6-16-36(2)3/h4-15,17-19H,16H2,1-3H3,(H, |
| Manufacturer | SIGMA-ALDRICH |
| Solubility | DMSO: 20 mg/mL, clear |
| Form | powder |
| Assay | ≥96% (HPLC) |
There are no downloads for this product.
